Veravas launched in 2017 with a mission that went far beyond just selling technology or building products. We want to impact healthcare, raising the bar for diagnostic accuracy, efficacy, and the scope of what can be tested. Below are some milestones and inflection points in this journey.
Today, the FDA issued an updated warning of biotin interference with certain laboratory tests. The FDA remains concerned about certain laboratory tests that have not addressed the risk of biotin interference. For example, the FDA has continued to receive adverse events reports indicating biotin interference caused falsely low troponin results.
Clinical Lab Products interviewed Veravas CEO, Carroll E. Streetman Jr., about the present and future of biotin interference removal.
True Diagnostics, Inc., a leading company for Point of Care answers, and Veravas, an emerging diagnostic company focusing on proprietary sample preparation products and new diagnostic tests, announced today their Strategic Alliance in the commercialization of VeraTest Biotin.
Register to receive updates and more information as it becomes available – from product launches to conference posters to novel partnerships and events.